This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bajaj, M. Articles by DeFronzo, R. A. Search for Related Content PubMed PubMed Citation Articles by Bajaj, M. Articles by DeFronzo, R. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Hazardous Substances DB GLUCOSE

Sustained Reduction in Plasma Free Fatty Acid Concentration Improves Insulin Action without Altering Plasma Adipocytokine Levels in Subjects with Strong Family History of Type 2 Diabetes

Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284-7886

Address all correspondence and requests for reprints to: Mandeep Bajaj, M.D., Assistant Professor, Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284-7886. E-mail: mandeepbajaj{at}hotmail.com.

To investigate the effect of a sustained (7-d) decrease in plasma free fatty acid (FFA) concentration in individuals genetically predisposed to develop type 2 diabetes mellitus (T2DM), we studied the effect of acipimox, a potent inhibitor of lipolysis, on insulin action and adipocytokine concentrations in eight normal glucose-tolerant subjects (aged 40 ± 4 yr, body mass index 26.5 ± 0.8 kg/m²) with at least two first-degree relatives with T2DM. Subjects received an oral glucose tolerance test (OGTT) and 120 min euglycemic insulin clamp (80 mU/m²·min) with 3-[³H] glucose to quantitate rates of insulin-mediated whole-body glucose disposal (Rd) and endogenous (primarily hepatic) glucose production (EGP) before and after acipimox, 250 mg every 6 h for 7 d. Acipimox significantly reduced fasting plasma FFA (515 ± 64 to 285 ± 58 µM, P < 0.05) and mean plasma FFA during the OGTT (263 ± 32 to 151 ± 25 µM, P < 0.05); insulin-mediated suppression of plasma FFA concentration during the insulin clamp also was enhanced (162 ± 18 to 120 ± 15 µM, P < 0.10). Following acipimox, fasting plasma glucose (5.1 ± 0.1 vs. 5.2 ± 0.1 mM) did not change, whereas mean plasma glucose during the OGTT decreased (7.6 ± 0.5 to 6.9 ± 0.5 mM, P < 0.01) without change in mean plasma insulin concentration (402 ± 90 to 444 ± 102 pmol/liter). After acipimox Rd increased from 5.6 ± 0.5 to 6.8 ± 0.5 mg/kg·min (P < 0.01) due to an increase in insulin-stimulated nonoxidative glucose disposal (2.5 ± 0.4 to 3.5 ± 0.4 mg/kg·min, P < 0.05). The increment in Rd correlated closely with the decrement in fasting plasma FFA concentration (r = –0.80, P < 0.02). Basal EGP did not change after acipimox (1.9 ± 0.1 vs. 2.0 ± 0.1 mg/kg·min), but insulin-mediated suppression of EGP improved (0.22 ± 0.09 to 0.01 ± 0.01 mg/kg·min, P < 0.05). EGP during the insulin clamp correlated positively with the fasting plasma FFA concentration (r = 0.49, P = 0.06) and the mean plasma FFA concentration during the insulin clamp (r = 0.52, P < 0.05). Plasma adiponectin (7.1 ± 1.0 to 7.2 ± 1.1 µg/ml), resistin (4.0 ± 0.3 to 3.8 ± 0.3 ng/ml), IL-6 (1.4 ± 0.3 to 1.6 ± 0.4 pg/ml), and TNF (2.3 ± 0.3 to 2.4 ± 0.3 pg/ml) did not change after acipimox treatment.

We concluded that sustained reduction in plasma FFA concentration in subjects with a strong family history of T2DM increases peripheral (muscle) and hepatic insulin sensitivity without increasing adiponectin levels or altering the secretion of other adipocytokines by the adipocyte. These results suggest that lipotoxicity already is well established in individuals who are genetically predisposed to develop T2DM and that drugs that cause a sustained reduction in the elevated plasma FFA concentration may represent an effective modality for the prevention of T2DM in high-risk, genetically predisposed, normal glucose-tolerant individuals despite the lack of an effect on adipocytokine concentrations.

This article has been cited by other articles:

				M. A. Abdul-Ghani, F. L. Muller, Y. Liu, A. O. Chavez, B. Balas, P. Zuo, Z. Chang, D. Tripathy, R. Jani, M. Molina-Carrion, et al. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E678 - E685. [Abstract] [Full Text] [PDF]

				S. Rigazio, H.-R. Lehto, H. Tuunanen, K. Nagren, M. Kankaanpaa, C. Simi, R. Borra, A. G. Naum, R. Parkkola, J. Knuuti, et al. The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E413 - E419. [Abstract] [Full Text] [PDF]

				K. Cusi, S. Kashyap, A. Gastaldelli, M. Bajaj, and E. Cersosimo Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1775 - E1781. [Abstract] [Full Text] [PDF]

				M. Bajaj, R. Medina-Navarro, S. Suraamornkul, C. Meyer, R. A. DeFronzo, and L. J. Mandarino Paradoxical Changes in Muscle Gene Expression in Insulin-Resistant Subjects After Sustained Reduction in Plasma Free Fatty Acid Concentration Diabetes, March 1, 2007; 56(3): 743 - 752. [Abstract] [Full Text] [PDF]

				G. Boden, C. Homko, M. Mozzoli, M. Zhang, K. Kresge, and P. Cheung Combined Use of Rosiglitazone and Fenofibrate in Patients With Type 2 Diabetes: Prevention of Fluid Retention Diabetes, January 1, 2007; 56(1): 248 - 255. [Abstract] [Full Text] [PDF]

				C. Hadigan, J. Liebau, M. Torriani, R. Andersen, and S. Grinspoon Improved Triglycerides and Insulin Sensitivity with 3 Months of Acipimox in Human Immunodeficiency Virus-infected Patients with Hypertriglyceridemia J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4438 - 4444. [Abstract] [Full Text] [PDF]

				S. R. Smith and P. W. F. Wilson Free Fatty acids and atherosclerosis--guilty or innocent? J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2506 - 2508. [Full Text] [PDF]

				T. W. Zderic and M. T. Hamilton Physical inactivity amplifies the sensitivity of skeletal muscle to the lipid-induced downregulation of lipoprotein lipase activity J Appl Physiol, January 1, 2006; 100(1): 249 - 257. [Abstract] [Full Text] [PDF]

				H. S. Jung, K.-H. Park, Y. M. Cho, S. S. Chung, H. J. Cho, S. Y. Cho, S. J. Kim, S. Y. Kim, H. K. Lee, and K. S. Park Resistin is secreted from macrophages in atheromas and promotes atherosclerosis Cardiovasc Res, January 1, 2006; 69(1): 76 - 85. [Abstract] [Full Text] [PDF]

				M. Bajaj, S. Suraamornkul, A. Romanelli, G. W. Cline, L. J. Mandarino, G. I. Shulman, and R. A. DeFronzo Effect of a Sustained Reduction in Plasma Free Fatty Acid Concentration on Intramuscular Long-Chain Fatty Acyl-CoAs and Insulin Action in Type 2 Diabetic Patients Diabetes, November 1, 2005; 54(11): 3148 - 3153. [Abstract] [Full Text] [PDF]

				J. M. Miles and M. D. Jensen Counterpoint: Visceral Adiposity Is Not Causally Related to Insulin Resistance Diabetes Care, September 1, 2005; 28(9): 2326 - 2328. [Full Text] [PDF]

				U. Salmenniemi, J. Zacharova, E. Ruotsalainen, I. Vauhkonen, J. Pihlajamaki, S. Kainulainen, K. Punnonen, and M. Laakso Association of Adiponectin Level and Variants in the Adiponectin Gene with Glucose Metabolism, Energy Expenditure, and Cytokines in Offspring of Type 2 Diabetic Patients J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4216 - 4223. [Abstract] [Full Text] [PDF]